Start Your Search
S02 - Symposium Honoring Dr. Gazdar's Legacy (Sign Up Required) (ID 97)
- Event: WCLC 2019
- Type: Symposium
- Track: Pathology
- Presentations: 1
- Now Available
- Moderators:Fred R. Hirsch, Tetsuya Mitsudomi, Ignacio Wistuba
- Coordinates: 9/07/2019, 17:30 - 19:00, Tokyo (1982)
S02.02 - Adi Gazdar’s Legacy (Now Available) (ID 2571)
17:30 - 19:00 | Author(s): Christine Burgess
Adi F. Gazdar (1937-2018) belongs to the 150 most successful scientists of all time. His impact in cancer research, virology, molecular pathology, cell biology, and many other disciplines was immense. A giant in lung cancer research, Dr. Gazdar pioneered numerous concepts and his work was seminal in the establishment of the current standard of care. He will be remembered as a prolific innovator, respected mentor, valued collaborator, and an altruistic human being. Here we will quantify the scientific legacy of Dr. Gazdar using various bibliometric analyses.
The impact of Dr. Gazdar’s work was evaluated with the use of a panel of bibliometric tools including PubMed, iSearch, iGrants, iCite, Google Scholar, Web of Science, Clarivate Analytics, and Dimensions.
Adi Gazdar has published more than 700 scientific publications that were cited more than 120,000 times, his H index is 171, and his most cited paper has more than 4000 citations (see Figure 1). His Weighted Relative Citation Ration (RCR) since 1994 is 1,283 with a mean RCR of 2.78 and median 1.33 per publication. By disciplines, most of his publications are in oncology, followed by studies on the respiratory system, cell biology, pathology, biochemistry and molecular biology, experimental medicine research, genetics, internal medicine, and biology. By scientific topics Dr. Gazdar published on lung cancer (small cell and non-small cell), tumor suppressor genes, viruses, breast cancer, allele loss, DNA methylation, risk factors, T cells, colorectal carcinoma, model systems, and growth factors and others. Many of his papers are related to drug development and testing and he published more than 10 papers on each of the following agents: decitabine, cisplatin, gefitinib, azacytidine, etoposide, insulin, doxorubicin, erlotinib, levodopa, tretinoin, and cyclophosphamide. Perhaps the most impact of Dr. Gazdar’s work had the creation and distribution of cell lines and models that allowed to characterize the retroviral particles in patients with T-cell lymphoma, test virtually all current chemo and targeted therapy agents used in the treatment of lung cancer, and define molecular subtypes of small cell and non-small cell lung cancers that are currently used in diagnosis. The National Cancer Institute US in collaboration with a team at the University of Texas Southwestern are currently assessing the tremendous impact that these cell lines had on all aspects of lung cancer research and standard of care. This Stewardship Project is led by Dr. James Mulshine from Rush University. The preliminary data generated by this project indicate that Dr. Gazdar's 278 lung cancer cell lines led to 33,207 publications, which were cited 2,968,974 times, referred by 4,700 patents, linked to 422 clinical trials, and produced 14,057 supporting grants by 1,019 funders world wide. An example for the most cited cell line H460 is in Figure 2. This cell line itself had 11,124 publications cited 347,117 times, was mentioned in 1,564 patents, was linked to 118 clinical trials and 4,890 grants funded by 717 organizations.
Doctor Adi F. Gazdar left behind an immense wealth of work that has changed cancer research and standard of care.